Literature DB >> 18954756

Vulvovaginal candidiasis and bacterial vaginosis.

Paul Nyirjesy1.   

Abstract

Vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are frequently encountered in clinical practice. Recent advances have furthered understanding of pathophysiology. Proper diagnosis, based on appropriate office and, in complicated cases, laboratory tests is the key to rational selection of therapy. For women who have routine uncomplicated episodes of VVC or BV, a variety of effective treatment options exists. Recurrent disease remains a challenge for these conditions but can often be managed successfully.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18954756     DOI: 10.1016/j.idc.2008.05.002

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  18 in total

1.  Prevalence of bacterial vaginosis and Candida among postmenopausal women in the United States.

Authors:  Joscelyn N Hoffmann; Hannah M You; E C Hedberg; Jeanne A Jordan; Martha K McClintock
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2014-11       Impact factor: 4.077

2.  Probiotic Properties of Lactobacillus crispatus 2,029: Homeostatic Interaction with Cervicovaginal Epithelial Cells and Antagonistic Activity to Genitourinary Pathogens.

Authors:  Vyacheslav Abramov; Valentin Khlebnikov; Igor Kosarev; Guldana Bairamova; Raisa Vasilenko; Natalia Suzina; Andrey Machulin; Vadim Sakulin; Natalia Kulikova; Nadezhda Vasilenko; Andrey Karlyshev; Vladimir Uversky; Michael L Chikindas; Vyacheslav Melnikov
Journal:  Probiotics Antimicrob Proteins       Date:  2014-12       Impact factor: 4.609

Review 3.  Treatment for recurrent vulvovaginal candidiasis (thrush).

Authors:  Georga Cooke; Cathy Watson; Laura Deckx; Marie Pirotta; Jane Smith; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2022-01-10

4.  Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus.

Authors:  Kristi L Strandberg; Marnie L Peterson; Ying-Chi Lin; Melinda C Pack; David J Chase; Patrick M Schlievert
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

5.  Biosynthesis and degradation of H2O2 by vaginal lactobacilli.

Authors:  Rebeca Martín; Juan E Suárez
Journal:  Appl Environ Microbiol       Date:  2009-11-30       Impact factor: 4.792

6.  Personal hygienic behaviors and bacterial vaginosis.

Authors:  Mark A Klebanoff; Tonja R Nansel; Rebecca M Brotman; Jun Zhang; Kai-Fun Yu; Jane R Schwebke; William W Andrews
Journal:  Sex Transm Dis       Date:  2010-02       Impact factor: 2.830

7.  Accuracy of the BD MAX™ vaginal panel in the diagnosis of infectious vaginitis.

Authors:  Amaia Aguirre-Quiñonero; I Sáez de Castillo-Sedano; F Calvo-Muro; A Canut-Blasco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-26       Impact factor: 3.267

8.  Chlorhexidine, clotrimazole, metronidazole and combination therapy in the treatment of vaginal infections.

Authors:  Shahla Mirzaeei; Maryam Zangeneh; Firoozeh Veisi; Somayeh Parsa; Maryam Hematti
Journal:  J Med Life       Date:  2021 Mar-Apr

Review 9.  Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review.

Authors:  Hans Verstraelen; Rita Verhelst; Kristien Roelens; Marleen Temmerman
Journal:  BMC Infect Dis       Date:  2012-06-28       Impact factor: 3.090

10.  Vaginal use of Ibuprofen isobutanolammonium (ginenorm): efficacy, tolerability, and pharmacokinetic data: a review of available data.

Authors:  Massimo Milani; Piero Iacobelli
Journal:  ISRN Obstet Gynecol       Date:  2012-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.